Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compulsory License On Table In UK For Orkambi

Executive Summary

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

Advertisement

Related Content

UK Buyers Club To Get Lower Cost Versions Of Vertex’s CF Drugs
‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England
UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi

Topics

Advertisement
UsernamePublicRestriction

Register

PS125460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel